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Abstract 
It has been proposed that gliomas contain a subpopulation of ‘Brain Tumor Stem 
Cells’ (BTSCs), which demonstrate resistance to conventional therapies. A potential 
component of the environment governing the behavior of these BTSCs is a class of 
transmembrane proteins with structural and signaling functions, the A-Disintegrin 
And Metalloproteases (ADAMs). In this study we confirm overexpression of 
ADAM10 and 17 in human glioma tissue compared to human controls, and especially 
in tumor sphere cultures thought to enrich for BTSCs. Inhibition of ADAM10/17 
function impairs the growth of tumor spheres with evidence of depletion of the sphere 
forming cell population. This results from a combination of reduced proliferation, cell 
death and a switch of sphere-forming cells away from symmetric self-renewal 
division towards neuronal differentiation. A developing appreciation of the role of 
ADAMs in BTSC promises insights into pathophysiology and potential therapeutic 
avenues in this intractable group of tumors. 
Keywords: brain tumor, ADAM10, ADAM17 
 
1. Introduction 
Gliomas are the most common malignant intrinsic primary brain tumors. The majority 
are high-grade lesions, with diffuse infiltration that precludes complete surgical 
resection. Debulking therefore remains the mainstay of management, and despite 
recent advances in chemotherapy and radiotherapy, median survival from diagnosis 
remains very short [1]. This limited progress reflects challenges specific to this 
pathology. 
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Firstly, high-grade lesions are genetically heterogeneous across the patient group, 
with data from The Cancer Genome Atlas suggesting four distinct subtypes [2]. 
Secondly, the blood brain barrier, where it remains intact, complicates delivery of 
chemotherapeutics. Finally, the tumor stem cell hypothesis holds that, in gliomas and 
other tumors, a small subpopulation of the neoplastic cells have tumor initiating 
capacity based on ‘stem’ properties of indefinite self-renewal and multipotency [3]. 
This subgroup of cells exhibits radio- and chemo- resistance, but gives rise to a 
rapidly-dividing downstream progenitor cell population which contributes to early 
recurrence after surgery [4]. While prospective identification of Brain Tumour Stem 
Cells (BTSCs) cells remains a significant challenge, sphere-forming cell populations 
believed to enrich for the BTSC fraction can be derived from primary brain tumour 
samples using established techniques. 
We have investigated the role of the transmembrane proteins, A-Disintegrin-And-
Metalloproteases (ADAMs), a family sharing a structure comprised intracellular 
protein interaction motifs, and multiple functional extracellular domains. These 
include an EGF-like sequence, cysteine rich and disintegrin domains, and, of key 
significance, most incorporate an extracellular metalloprotease active on growth 
factor ligands and receptors, cytokines and adhesion molecules. Of the many ADAMs 
identified, ADAM10 and 17 are the most highly conserved, with orthologs 
demonstrated in yeast, drosophila and primitive chordates [5]. These two ADAMs 
also have established roles in CNS development, promoting stem cell proliferation 
and migration [6], and mediating adhesion and neurite outgrowth. These functions, 
which render ADAM10 and 17 strong candidate regulators of tumor stem cell 
activity, reflect a range of enzymatic and structural interactions. 
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The enzyme domains of ADAM10 and 17 share similar specificity, and activate 
signaling pro-peptides by cleavage. In the case of ADAM10, this activity applies to 
Pro-TNF-alpha, Pro-EGF, Notch and Ephrin signaling cascades. These cascades 
represent key regulatory mechanisms in the control of cell growth and lineage 
determination, and deregulation of each is a conserved feature across many tumor 
types [7; 8]. The protease domain of ADAM17 is also active on a range of growth 
factors and related receptors, including Pro-TNF-alpha, TNF receptor, Pro-HB-EGF, 
Notch1, TGF-alpha, IL-6, L-selectin and amyloid precursor protein [5; 9]. The EGF 
Receptor-PI3 Kinase-Akt pathway appears central to a role for ADAM17 in inducing 
proliferation and migration [8]. Notch signaling, recognized as essential to 
maintenance of normal stem cell populations [10], is one example of functional 
overlap between ADAM10 and ADAM17, with evidence that ADAM10 is essential 
for ligand induced Notch signaling [11; 12], whereas ligand independent signaling is 
dependent on ADAM17 [13; 14]. ADAMs 10 and 17 are also thought to contribute to 
cell-cell signaling via their disintegrin domain [15], and there is substantial evidence 
of protease involvement in extracellular matrix degradation associated with tumor 
invasion[5; 9], [16], [17], [18; 19; 20] 
Overexpression of ADAMs 10 and 17, among others, has been reported in gliomas 
[21; 22], as in other cancers.  Further, overexpression of ADAM17 correlates with 
poor prognosis [23] and artificial overexpression of ADAM17 in astrocyte cell lines is 
sufficient to confer a malignant phenotype including non-adherent growth and 
increased proliferation and invasion [24], although the mechanism is unknown. 
Equally, recent evidence points to compensatory upregulation of ADAM expression 
in breast cancers in response to monoclonal antibody therapies targeted at key 
ADAM-dependent signaling cascades [25]. 
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In this study we have sought to establish the expression profile of ADAM molecules 
in the sphere-forming cell fraction believed to enrich for BTSCs[26], and their 
functional significance in the expansion and differentiation of these tumors. 
 
2. Materials and Methods 
2.1 Materials  
All procedures followed are in accordance with the ethical standards of the Helsinki 
declaration (1964, 2008) of the World Medical Association. Human tissue was 
collected according to Ethical Approval obtained from the Berkshire Local Research 
Ethics Committee (REC 08/H0505/165, CI-WPG), with informed written consent. 
Tumor samples were obtained at the time of operative resection, selecting material 
from the enhancing tumor rim by preference from tumors of astrocytic and 
oligodendroglial lineage, WHO grade II, III and IV. Normal adult temporal cortex 
tissues were obtained at amygdalohippocampectomy for intractable epilepsy 
(Southampton and West Hampshire Local research Ethics Committee REC 
07/H0504/195, CI-WPG). Embryonic neural tissues (gestation age 7-10 weeks) were 
obtained at termination of pregnancy (Southampton and West Hampshire Local 
research Ethics Committee REC 296/00). The selective inhibitor of ADAM10 
GI254023X (Inhibition IC50 (ADAM10)/ IC50 (ADAM17) = 102.0), and inhibitor of 
ADAM10 and 17 GW280264X (Inhibition IC50 (ADAM10)/ IC50 (ADAM17) = 1.4) 
were provided by Prof Andreas Ludwig, Aachen University, Germany [27; 28]. Anti- 
ADAM 10 and ADAM 17 antibodies, for use in blocking experiments, were sourced 
commercially, from Chemicon and Calbiochem respectively. IgG1κ isotype control 
was from Biolegend (#400101). 
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2.2 Sphere Culture 
On harvesting, all glioblastoma (WHO IV) tissues were enzymatically and 
mechanically dissociated to single cell suspensions according to established protocols 
for culture of brain tumor initiating cells [29; 30], and cultured in single cell 
suspension at a density of 10cells/µL. Growth medium consisted of Neurobasal-A 
(Invitrogen), supplemented with B27, L-glutamine 2mM, antibiotic/antimycotic 
preparation, and growth factors (human FGFb10ng/mL, human EGF 20ng/mL and 
heparin 2µg/mL). 
Medium was changed twice weekly and spheres were passaged when the majority 
exceeded 100µm in diameter. Passaging was accomplished by centrifugation, then 25 
cycles of mechanical trituration using a 1mL pipette, followed by resuspension at 
10cells/µL in fresh medium. At the fifth passage, the sphere cell line was considered 
established, and ready for use in quantitative assays, RNA extraction, or 
cryopreservation [31]. Sphere counts were performed at day10 unless otherwise 
specified, and reflect the number of spheres >100µm in diameter per well, averaged 
across at least 3 wells per sample. 
2.3 Proliferation and Survival Analysis 
Monolayer cultures were used to assess viability and proliferation 3 days after cell 
plating. Cells in these cultures were plated at equal live cell density on coverslips 
coated with 0.0015% poly-L-ornithine and 50µg/mL laminin in growth medium. For 
proliferation, BrdU labeling was used to allow determination of mitotic and labeling 
indices and was accomplished by exposing the cultures to 20µM BrdU over a period 
of 2 hours, followed by fixation and immunostaining. Growth fraction and mitotic 
index were calculated as the proportion of DAPI-labeled cells stained respectively 
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with Ki67 and BrdU. Labeling index was calculated as the proportion of Ki67-
labelled cells stained with BrdU. Cell survival and cell death were quantified by using 
mitotracker green (MTG, 0.1µM) and propidium iodide (PI, 5µg/ml), respectively. 
Propidium iodide and nuclear stain 4’,6-diamidino-2-phenylindole (DAPI, 20µg/ml) 
were added to fresh growth media and incubated with live cultures for 40 minutes at 
37°C. This medium was then removed, replaced with MTG-containing medium and 
incubated at 37°C for 40 minutes, before this was replaced with fresh medium for 
imaging. Cell death was quantified as the proportion of cells DAPI and PI positive, 
DAPI and MTG positive cells were recorded as live cells, and cells positive for all 
three markers were depicted as dying cells. Images were averaged across as least three 
wells per condition.  
2.4 Differentiation Culture 
In order to promote differentiation, spheres were collected by pipetting and triturated 
to a monocellular suspension. They were then plated on coverslips coated with 
0.0015% poly-L-ornithine and 50µg/mL laminin, in Neurobasal-A containing 10% 
Fetal Bovine Serum. Medium was changed twice weekly and cells were fixed with 
4% paraformaldehyde in PBS after 8 days. 
2.5 RNA extraction and RT-qPCR 
Tissue and sphere samples were stabilized by treatment with RNA Later (Qiagen), 
and then frozen to -80°C for storage. Extraction of purified RNA was performed 
using Qiagen’s RNeasy Mini kit according to protocol. cDNA was generated using 
SuperScriptTM III Cells Direct cDNA Synthesis Kit (InvitrogenTM life technologies) 
and subsequently diluted to 5ng/µL for qPCR. 
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cDNA was amplified using appropriate primers and Precision real-time PCR 
MasterMix with SYBRgreen (PrimerDesign Ltd, Southampton) in a thermocycler 
(Rotor-Gene 6000, Corbett Robotics. Ltd). A panel of 12 housekeeping genes was 
assessed for suitability using geNorm software (PrimerDesign Ltd, Southampton), and 
the genes ATP5B and EIF4A2 were selected as the most stable and subsequently used 
for normalization of all samples tested. 
2.6 Time-lapse Videomicroscopy 
Time-lapse videomicroscopy was performed over 48 hours, at 80 locations 
(sequences) throughout the wells (40 control, 40 ADAM10/17 inhibition conditions), 
with visual confirmation of consistent cell density between locations prior to analysis. 
Monolayer cultures were used with cells plated at equal live cell density on coverslips 
coated with  0.0015% poly-L-ornithine and 50µg/mL laminin in growth medium. The 
images were analyzed to ascertain the number of divisions per sequence, the number 
of daughter cells that had migrated from the field of view, and the number of divisions 
resulting in at least one daughter cell death (which was assessed morphologically by a 
darkened cell body and lack of movement/contact with other cells). Cell division 
types (asymmetric or symmetric) and differentiation were analyzed by the use of 
gridded coverslips to track daughter cells during time-lapse videomicroscopy and 
subsequent staining with Nestin (stem/progenitor cell marker) and Beta-III-tubulin 
(early neuronal marker). 
2.7 Immunostaining 
Tissue and sphere 10µm sections were obtained by embedding fragments fixed in 
4%PFA and sectioning on a cryostat. 
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Staining was performed on cells and sections using antibodies against Nestin 
(Millipore, mouse 1:500), GFAP (Dako, rabbit 1:500), Beta-III-tubulin (clone Tuj-1, 
Sigma, mouse 1:200), ADAM10 (Chemicon, rabbit 1:100), ADAM17 (Calbiochem, 
rabbit 1:100), BrdU (Serotec, rat 1:200) and Ki-67 (ebioscience.com, mouse 1:500). 
Secondary antibodies used were Donkey Alexa Fluor 488 and 555 raised against 
appropriate primary sera (Invitrogen). 
For quantification, cell counts were averaged across at least three randomly selected 
20x fields.  
2.8 ADAM17 enzymatic activity assay 
The enzyme activity of ADAM17 was quantified by fluorometric analysis using 
InnoZyme™ TACE Activity Kit (Calbiochem #CBA042). To assess inhibitor 
activity, 10-200ng/ml of purified human TACE protein was incubated on ice for 30 
minutes with 2ug/ml of anti-ADAM17 (Calbiochem #PC491) or IgG1κ isotype 
control (Biolegend #400101) before following the activity kit protocol. 
 
3. Results 
3.1 ADAM10 and ADAM17 are highly expressed in high-grade glial tumors, and in 
tumor spheres derived from them. 
Given that Nestin is highly expressed in dividing stem and progenitor cells, both 
normal and cancerous, we would expect overexpression in embryonic tissue and in 
tumors, especially high-grade lesions, compared to normal adult brain tissue. We 
expect further overexpression in sphere cultures believed to enrich for the stem 
component. In keeping with this hypothesis, RT-qPCR established Nestin mRNA 
levels compared to normal cortex samples, at 10.9 (WHO Grade II glioma), 13.9 
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(WHO Grade III glioma), 27.8 (WHO Grade IV glioma) and 52.8 (Grade IV glioma 
spheres) (figure 1A,B), and for controls, 5.6 (embryo tissue) and 25.1 (embryo 
spheres). 
RT-qPCR established ADAM10 mRNA levels compared to normal cortex samples, at 
0.8 (WHO Grade II Glioma), 2.1 (WHO Grade III glioma), 2.7 (WHO Grade IV 
glioma) and 3.2 (Grade IV Glioma spheres; figure 1C,D), and for controls, 1.6 
(embryo tissue) and 4.8 (embryo spheres).  
ADAM17 mRNA levels were expressed compared to normal cortex samples obtained 
during resective non tumour epilepsy surgery, at 2.6 (WHO Grade II Glioma), 2.9 
(WHO Grade III Glioma), 3.7 (WHO Grade IV Glioma) and 4.2 (Grade IV Glioma 
spheres; figure 1E,F), and for controls, 0.8 (embryo tissue) and 1.2 (embryo spheres).  
Immunostaining revealed Nestin staining throughout cultured tumor spheres. Focal 
high-level expression (figure 1G) with colocalized GFAP staining, a pattern 
associated with a stem cell component in previous reports, was noted. Similarly 
CD133 expression was confirmed by staining of tumour and sphere specimens (data 
not shown). To confirm expression in brain tumor stem/ progenitor cells, 
immunohistochemistry was performed on WHO Grade IV glioma tissues and tumor 
spheres for ADAM10, ADAM17 and Nestin (figure 1G,H). Confocal analysis showed 
colocalization of ADAM10 or 17 with Nestin (higher magnification pictures on figure 
1G,H), both on tissue and spheres, compatible with ADAM10 and 17 expression by 
BTSCs and/or progenitors. The cellular staining patterns for ADAM10 or 17 are not 
identical with that of Nestin due to different cellular compartment localization, but co-
expression within single cells can be identified. Primary antibody negative controls 
showed no staining (data not shown).  
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3.2 ADAM10/17 inhibition impairs tumor sphere formation. 
To investigate the role of ADAM10 and 17 in high grade tumor and spheres from 
glioblastomas, the effects of pharmacological inhibitors of ADAM10/17 function 
were assessed by counting spheres at culture day 10. The pharmacological inhibitors 
used are well-characterized from the standpoint of ADAM-10/-17 inhibition and a 
few other metalloproteinases [27; 28], 
Inhibition of ADAM10 alone produced a median reduction in number of spheres 
across the six cell populations studied to 28% of baseline, while inhibition of 
ADAM10/17 together produced a reduction in number of spheres to 14% of baseline 
(figure 2A,C). The observed effect was concentration dependent (figure 2A,C), and 
varied between sphere lineages studied (figure 2B,D). Across six lineages, ADAM17 
mRNA levels were a significant predictor of the reduction in sphere numbers in the 
presence of the ADAM 10/17 inhibitor GW280264X (10µM) (Spearman r=0.886, 
p=0.019). The levels of ADAM10 mRNA were not significantly correlated with the 
decrease in sphere formation induced by ADAM10 inhibition by GI254023X (10µM) 
(Spearman r=0.700, p=0.188) and by ADAM10/17 inhibition by GW280264X 
(10µM) (Spearman r=0.464, p=0.354). 
In order to confirm that these results derived from blockade of ADAM10 and 17 
function as opposed to non-specific actions of the inhibitors applied, tumor sphere 
formation was assayed in the presence of blocking antibodies (2µg/mL) specific to 
these metalloproteases [32; 33; 34; 35; 36], where significant reduction in sphere 
growth was again observed (figure 2E,F). As control, a non-specific IgG did not have 
any effect (figure 2G). We also checked that the blocking antibodies indeed decreased 
ADAM17 enzymatic activity compared to control and non-specific IgG (figure 2H). 
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3.3 ADAM10/17 inhibition decreases the survival rate of daughter cells after 
progenitor cell division. 
A number of mechanisms might account for the observed reduction in sphere 
formation following ADAM inhibition, including reduced cell survival, reduced 
proliferation, and/or premature differentiation. Using propidium iodide staining of six 
primary glioblastoma cultures, we established no difference in overall cell survival in 
the bulk tumor population at day 3 between control cultures (median 50%, IQR 26-
67%), and those exposed to anti-ADAM10 (median 44%, IQR 24-78%) or anti-
ADAM17 (median 53%, IQR 35-75%) antibodies.  
Next, survival of the dividing cells of the tumor was analyzed using time-lapse 
videomicroscopy. In the population of daughter cells seen to arise from progenitor 
divisions, the addition of anti-ADAM10/17 blocking antibodies (2µg/mL) or the 
inhibitor GW280264X (10µM) produced a significant increase in cell death over the 
48 hour period (figure 3A,B). 
3.4 ADAM10/17 inhibition decreases proliferation. 
Growth fraction and mitotic index were calculated as the proportion of DAPI-labeled 
cells stained with Ki67 and with BrdU respectively, while the labeling index was 
calculated as the proportion of Ki67-labelled cells stained with BrdU (figure 3C). In 
ADAM10/17 inhibition conditions, a trend towards reduced division parameters in the 
bulk population was noted, and when divisions were analyzed with time-lapse 
videomicroscopy, we confirmed a reduced number of cell divisions over a 48 hour 
period with ADAM10/17 inhibition (figure 3D). 
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3.5 ADAM10/17 inhibition depletes the stem/progenitor pool by favoring neuronal 
differentiation over symmetric self-renewal division. 
Under differentiation conditions, a significant increase in the proportion of cells 
expressing the neuronal lineage marker Beta-III-tubulin, was observed with 
application of GW280264X (10µM) (figure 4A), pointing toward a more central role 
of ADAM17 compared to ADAM10 (no effect with GI254023X). There was no 
significant effect on the overall proportion of cells expressing Nestin or GFAP. 
Among the Beta-III-tubulin positive cells, around 40% co-express Nestin (data not 
shown) which might represent an intermediate state between Nestin positive 
progenitors and Beta-III-tubulin positive neuroblasts. The increasing trend is seen in 
both Beta-III-tubulin+Nestin+ and Beta-III-tubulin+Nestin- cell populations (data not 
shown). These results fit with an effect recently reported in ADAM10 knockout mice 
[7], which demonstrate premature differentiation of neural stem cells. 
To dissect this overall effect, immunostaining of the daughter cells of progenitor 
divisions (figure 4B,C) identified on time-lapse microscopy was used. This confirmed 
an increase in the number and proportion of daughter cells expressing Beta-III-tubulin 
in the presence of ADAM10/17 blocking antibodies (2µg/mL) compared to control. 
Importantly, after 2 days in growth condition, the majority of daughter cells continued 
to express Nestin in control conditions (38 of 40 cells analyzed), but this was not the 
case when ADAM10/17 were inhibited (7 of 24 cells analyzed) (figure 4C). This was 
confirmed by a decrease in the number of Sox2 positive cells when ADAM10/17 
were inhibited (data not shown). ADAM10/17 inhibition effectively abolished 
symmetric division of Nestin positive Beta-III-tubulin negative cells (figure 4D) 
consistent with a fate-determining switch away from maintenance of the Nestin 
positive BTSC/progenitor cell pool, and consistent with the observed reduction in 
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sphere formation. As previously mentioned this effect on the Nestin positive cells was 
not evident on staining of bulk tumor after 8 days in differentiation conditions (figure 
4A), perhaps because Nestin+ BTSCs are outnumbered by a much larger non-
proliferating Nestin+ component. An increase in the double negative cell fraction 
(Nestin- and Beta-III-tubulin -) is also shown: these cells may begin to differentiate 
without yet expressing Beta-III-tubulin, or express other lineage markers. 
When analyzing pairs of daughter cells (excluding pairs with death of one of the 
daughter cells), a switch from symmetric self-renewal division in control conditions to 
asymmetric differentiating division occurs when ADAM10/17 are inhibited (figure 
4D). 
Our findings show depletion of the stem/progenitor cell population when 
ADAM10/17 are inhibited, due to reduced proliferation, a switch towards a 
asymmetric differentiation division type, daughter cell death, and an increase in 
neuronal differentiation. 
3.6 ADAM10/17 inhibition impacts on the cell morphology. 
ADAM10 inhibition induced a significant decrease of Beta-III-tubulin+ cells with 
neurites, and ADAM10/17 inhibition caused a significant reduction in the proportions 
of Nestin+ cells, GFAP+ cells and Beta-III-tubulin+ cells with processes (figure 
4E,F). 
 
4. Discussion 
The established functions of ADAM10 and ADAM17 are integral to a number of 
aspects of the neoplastic phenotype, including autonomous growth signaling, invasion 
and neovascularization [5; 37]. 
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Here we have shown that ADAM10 and ADAM17 are overexpressed in glial tumors, 
in keeping with expression data from the Rembrandt database [38]. ADAM10 is also 
overexpressed in embryonic tissue and spheres, but this is expected given the 
established role in development[7], and indeed is compatible with expression within, 
and functional significance relating to, the stem cell component, whether normal or 
cancerous. Immunostaining points to colocalization of ADAM10/17 with the stem 
and progenitor cell marker Nestin.  
We have demonstrated significant impairment of sphere growth associated with 
inhibition of ADAM10/17 protease function. Further we have shown that this effect is 
due to changes in survival, proliferation and differentiation. BTSCs stain with Nestin, 
but are thought to represent a small fraction of the tumor and indeed of the resulting 
sphere cultures: the majority of Nestin positive cells are likely to represent 
downstream progenitors [39]. In keeping with a specific impact on the former 
population, we have shown that overall Nestin staining in the tumor does not decrease 
with ADAM10/17 inhibition, but that in the daughter cell population identified on 
time-lapse videomicroscopy, few retain this marker after 48 hours due to a significant 
reduction in symmetric division of this cell type. We propose that maintenance and 
expansion of the BTSC pool, which depends on symmetric cell division to produce 
two Nestin positive Beta-III-tubulin negative daughter cells, is compromised by 
inhibition of ADAM10 and 17 function (figure 4D). Depletion of the BTSC pool by 
this mechanism could account for the reduction in divisions observed in these 
conditions, and indeed impaired sphere growth. We suggest therefore that ADAM10 
and/or 17 may be necessary for self-renewal and ultimately maintenance of the brain 
tumour sphere forming cell population. The involvement of other related enzymes is 
however not ruled out. 
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Despite the staining evidence of premature differentiation, we noted a marked 
impairment in development of cell processes in the presence of ADAM inhibitors. 
This agrees with the reported role of ADAM10/17 on neurite growth [40], and points 
to preservation of this role in the tumor context.  
Our study has not addressed the role of ADAMs in the diffuse infiltration and 
invasion that characterizes high grade gliomas. Both ADAM10 and ADAM17 have 
also been implicated here, and are likely to exert a combination of effects, on 
extracellular matrix remodeling, signaling and angiogenesis among others [41; 42]. It 
is likely that some of the observed variability in ADAM overexpression and effect 
may be accounted for within emerging molecular classifications of these tumors [43], 
and investigation of these avenues might be expected to yield insights into 
pathophysiology, and perhaps ultimately targeted therapeutic approaches. 
Further work must aim to clarify the role of ADAMs using RNA interference and 
manipulation of distal components of the signaling pathways involved. Notch 
signaling, for example, is now a promising therapeutic target [7; 44]. Only through 
precise characterization of the deregulation of these pathways at all levels can we 
evaluate the contribution of each ADAM, and establish the potential for 
pharmacological intervention. 
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9. Figure legends 
Figure 1: ADAM10 and 17 expression in brain tumor tissue and spheres 
Relative mRNA levels of Nestin (A and B), ADAM10 (C and D), and ADAM17 (E 
and F) to adult cortex tissue expression after RT-qPCR. Correlations with the grade of 
the brain tumors (A, C and E), as well as comparisons between tumor spheres and 
embryonic spheres (B, D and F) are presented. Data represent n=3 (adult tissue), n=1 
(tissue WHO Grade II), n=3 (tissue WHO Grade III), n=22 (tissue WHO Grade IV), 
n=11 (spheres WHO Grade IV), n=9 (embryo tissue), n=3 (embryo spheres) samples. 
Medians were compared using Kruskal-Wallis followed by Dunn multiple 
comparison test *p<0.05, and error bars represent interquartile ranges. Images 
confirm expression of ADAM10 and ADAM17 (green) by immunostaining in tumor 
spheres (G) and brain tumor tissue WHO Grade IV (H) and confocal colocalization 
with Nestin (red) and DAPI (blue). Scale bar in upper rows=25µm; in lower 
rows=10µm. White arrows point to double labeled cells. 
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Figure 2: ADAM10/17 inhibition alters tumor sphere formation 
(A) Quantification of the number of spheres per well in the presence of varying 
concentrations of the ADAM10 inhibitor GI254023X, expressed as percentage 
of control. Data represent n=6 independent samples. Means ± SEM were 
compared using Kruskal-Wallis followed by Dunn multiple comparison test. 
*p<0.05 when compared to control. 
(B) Quantification of the number of spheres per well across 6 tumor samples, 
(002/ to 036/) with or without GI254023X (10µM). Data represent n=3 wells 
per sample. Means ± SEM were compared using student T-tests. *p=0.008 for 
002/; p=0.383 for 004/; *p=0.014 for 005/; *p=0.007 for 010/; *p=0.002 for 
035/; *p=0.01 for 036/ when compared to 0µM.  
(C) Quantification of the number of spheres per well in the presence of varying 
concentrations of the ADAM10/17 inhibitor (GW280264X), expressed as 
percentage of control. Data represent n=6 independent samples. Means ± SEM 
were compared using Kruskal-Wallis followed by Dunn multiple comparison 
test. *p<0.05 when compared to control or 0.1µM. 
(D) Quantification of the number of spheres per well across 6 tumor samples, 
(002/ to 036/) with or without GW280264X (10µM). Data represent n=3 wells 
per sample. Means ± SEM were compared using student T-tests.  *p=0.036 for 
002/; *p=0.03 for 004/; p=0.127 for 005/; *p=0.003 for 010/; p=0.1 for 035/ 
(Mann Withney test); *p=0.006 for 036/ when compared to 0µM. 
(E) Quantification of the number of spheres per well for sample 004/ with or 
without anti-ADAM10 or ADAM17 antibodies (2µg/mL). Data represent n=6 
wells per group. Means ± SEM were compared using one way ANOVA 
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followed by Tukey multiple comparison test *p=0.001 when compared to 
control. 
(F) Quantification of the number of spheres per well for sample 005/ with or 
without anti-ADAM10 or ADAM17 antibodies (2µg/mL). Data represent n=6 
wells per group. Means ± SEM were compared using one way ANOVA 
followed by Tukey multiple comparison test *p=0.039 when compared to 
control. 
(G) Quantification of the number of spheres per well for sample 037/ with or 
without non-specific IgG, or anti-ADAM10 and 17 antibodies (2µg/mL). Data 
represent n=3-6 wells per group. Means ± SEM were compared using one way 
ANOVA followed by Bonferonni multiple comparison test *p<0.001 when 
compared to control or IgG. 
(H) Quantification of the ADAM17 enzymatic activity with or without non-
specific IgG, or anti-ADAM17 antibody (2µg/mL). Data represent n=3-5 wells 
per group. Means ± SEM were compared using student t-test *p=0.003 for left 
graph and *p=0.039 for right graph when compared to control or IgG 
respectively. 
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Figure 3: ADAM10/17 inhibition decreases the survival rate of daughter cells and 
the proliferation rate of progenitors 
(A)  Sample time-lapse videomicroscopy images demonstrating a progenitor cell 
division with the 2 corresponding daughter cells (arrows, left and middle) 
followed by death of a daughter cell (right, horizontal arrow). 
(B)  Daughter cell death rates following progenitor cell division over a 48 hour 
time-lapse videomicroscopy experiment with ADAM 10 and 17 blocking 
antibodies (2µg/mL)  (61 fields) and control (57 fields) conditions are 
compared. Cell death in the daughter cell population is significantly increased 
by ADAM10/17 inhibition. (χ2 =8.343, df=1, * p=0.004) 
(C) The mitotic index measures the proportion of cells (DAPI+) which are in S 
phase (BrdU+) at day 3 in culture (one way ANOVA p=0.265). The growth 
fraction indicates the proportion of cells (DAPI+) which are proliferating 
(Ki67+) (one way ANOVA p=0.797). The labeling index quantifies the 
proportion of proliferating cells (Ki67+) which are in S-phase (BrdU+) (one 
way ANOVA p=0.310). Data represent n=4 independent samples.  
(D)  The total number of divisions observed over a 48 hour period with ADAM 10 
and 17 blocking antibodies (2µg/mL) and control conditions are compared. 
Uniform plating density between conditions was confirmed on the initial 
images obtained. Significantly fewer divisions occur in ADAM10/17 
inhibition conditions (Mann Whitney U=1373.500, * p=0.047). 
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Figure 4: ADAM10/17 inhibition directs brain tumor stem cells away from 
symmetrical expansion and towards neuronal differentiation 
(A) Quantification of Nestin, GFAP and Beta-III-tubulin positive cells after 8 days 
in differentiation culture conditions, as a percentage of the total number of 
cells quantified using DAPI. Data represent quantification of 3 fields/sample, 
n=3 samples. Mean ± SEM were compared using one way ANOVA followed 
by Holm-Sidak multiple comparison test. *p<0.001when compared to control 
or GI254023X. 
(B) Representative images obtained using time-lapse videomicroscopy illustrate a 
cell division, with the progeny (arrows) subsequently fixed and co-stained for 
Beta-III-tubulin (green) and Nestin (red). 
(C) The Beta-III-tubulin (Beta-III-T) and Nestin co-staining of the daughter cells 
generated during 48 hours of time-lapse imaging was examined in control 
conditions (n=40), and in the presence of ADAM 10 and 17 blocking 
antibodies (2µg/mL) (n=24). In inhibition conditions, a substantial decrease in 
the Beta-III-tubulin- Nestin+ stem and progenitor daughter cell fraction is 
evident, and the proportion of Beta-III-tubulin+ cells is increased (χ2 =38.398, 
df=3, p<0.001). 
(D) Surviving pairs of daughter cells (excluding pairs with death of either 
daughter cell) from time-lapse videomicroscopy were analyzed in control 
conditions (n=15 pairs) and ADAM10/17 inhibition (n=9 pairs). Inhibition 
conditions are associated with abolition of symmetrical cell division by the 
Nestin+ Beta-III-tubulin- component corresponding to BTSCs (Fisher exact 
test =20.181, p<0.001). 
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(E) Representative images illustrate the staining results quantified in (A) and (F):  
Beta-III-tubulin (green), GFAP (red), Nestin (green), DAPI (blue) are stained 
in control conditions or with GW280264X (10µM). Scale bar=25µm. 
(F) Quantification of cells with a differentiated morphology (presence of long 
processes) after 8 days in differentiation culture conditions, as percent of 
numbers of cells positive for Nestin, GFAP or Beta-III-tubulin. Data represent 
quantification of 3 fields/sample, n=3 samples. Mean ± SEM were compared 
using Kruskal-Wallis (for Nestin and GFAP) or one way ANOVA (for Beta-
III-tubulin) followed by Tukey multiple comparison test. *p<0.05 when 
compared to control; **p<0.05 when compared to control or GI254023X. 
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